The global gene therapy market , categorized by vectors (non-viral, including oligonucleotides, and viral, comprising retroviral and adeno-associated vectors), indication (covering cancer, neurological, hepatological diseases, and Duchenne muscular dystrophy), and delivery method (in vivo and ex vivo), is poised for remarkable expansion. It is projected to reach a valuation of USD...